Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Ross C. Donehower

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-4664-8916; OpenAlex author ID A5110294409. Sources: ClinicalTrials.gov.

Their work

Papers
13
Trials
1
Grants
0
Labs led
0
Collaborators
81
Papers, trials and grants by year

2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: 2 papers · 2013: 4 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 13

  1. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  2. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  3. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  4. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.17237↗
  5. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  6. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  7. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic… Co-author DOI 10.1016/j.ijrobp.2013.06.2039↗
  8. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Co-author DOI 10.1097/cji.0b013e31829fb7a2↗
  9. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. Co-author DOI 10.1200/jco.2012.44.7516↗
  10. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-011-1704-y↗
  11. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9818-6↗
  12. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10637-010-9413-7↗
  13. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-10-0893↗

Trials 1

  1. DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer Study chair NCT00024375↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. Laheru · 13 shared papers, 2011–2022 · strength 0.55
  2. Dung Thi Le · 9 shared papers, 2012–2022 · strength 0.45
  3. Ana De Jesus‐Acosta · 8 shared papers, 2011–2022 · strength 0.41
  4. Lei Zheng · 7 shared papers, 2012–2022 · strength 0.39
  5. Nilofer Saba Azad · 5 shared papers, 2016–2022 · strength 0.33
  6. Christopher Lee Wolfgang · 6 shared papers, 2013–2022 · strength 0.28
  7. Elliot K. Fishman · 4 shared papers, 2016–2022 · strength 0.27
  8. Amy Hacker‐Prietz · 4 shared papers, 2013–2022 · strength 0.25
  9. Ralph H. Hruban MD · 6 shared papers, 2011–2021 · strength 0.25
  10. Jin Peng He · 3 shared papers, 2017–2022 · strength 0.23
  11. Valerie Lee · 3 shared papers, 2017–2022 · strength 0.23
  12. Amol Kumar Narang · 3 shared papers, 2017–2022 · strength 0.23
  13. Alison P. Klein · 3 shared papers, 2011–2022 · strength 0.20
  14. Robert A. Anders · 2 shared papers, 2021–2022 · strength 0.18
  15. Ding Ding · 2 shared papers, 2021–2022 · strength 0.18
  16. William R. Burns · 2 shared papers, 2021–2022 · strength 0.18
  17. Vikesh K. Singh · 2 shared papers, 2021–2022 · strength 0.18
  18. Eun Ji Shin · 2 shared papers, 2021–2022 · strength 0.18
  19. Richard Andrew Burkhart · 2 shared papers, 2021–2022 · strength 0.18
  20. Michael J. Wright · 2 shared papers, 2021–2022 · strength 0.18
  21. Jun Yu · 2 shared papers, 2021–2022 · strength 0.18
  22. Atif Zaheer · 2 shared papers, 2021–2022 · strength 0.18
  23. Nicholas Jason Roberts · 2 shared papers, 2021–2022 · strength 0.18
  24. Anne Marie Lennon · 2 shared papers, 2021–2022 · strength 0.18
  25. Ammar A. Javed · 2 shared papers, 2021–2022 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.